|Bid||0.00 x 1000|
|Ask||0.00 x 1800|
|Day's Range||6.07 - 6.45|
|52 Week Range||2.07 - 9.30|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022 - Apr 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.33|
If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...
Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe transaction demonstrates the strength of F-star’s differentiated bispecific antibody technology and provides backing from a top 40 global pharmaceutical company to accelerate growth and unlock potentialF-star’s unique next-generation tetravalent (2+2) bispecific antibody platform comple
F-star Therapeutics, Inc. ( NASDAQ:FSTX ) just released its latest quarterly results and things are looking bullish...